Izun Pharma Appoints Jack Talley as Chief Executive Officer

NEW YORK--(BUSINESS WIRE)--

Izun Pharmaceuticals Corporation ("Izun", izunpharma.com), a clinical stage company focused on developing high efficacy products based on compounds derived from botanical sources announced today that it has appointed Jack Talley as its Chief Executive Officer.

Mr. Talley brings over 30 years of relevant experience in the pharmaceutical industry, fifteen of which were as CEO in emerging pharmaceutical companies. Most recently, Mr. Talley was CEO and President of Alissa Pharma, a company focusing on radioimmunotherapy utilizing novel targeted antibodies in the treatment of solid tumors. Prior to that he was the CEO and President of EpiCept where he oversaw the establishment of EpiCept as a public company. During his tenure, Mr. Talley successfully raised in excess of $100 million for the company and secured licenses for a number of its products. Mr. Talley also served as CEO and President for Consensus Pharmaceuticals, President and Chief Operating Officer of Penwest Pharmaceuticals Company where he established an alliance with Endo Pharmaceuticals, which provided the foundation for the acquisition of Penwest by Endo and a Vice President of Marketing at Sanofi.

Dr. Bill Levine, the founder and previous CEO of Izun, who has now assumed the role of Executive Chairman stated, "Jack brings invaluable expertise in both drug development and product commercialization to Izun. His leadership skills, breadth of knowledge of the industry, commercialization experience, proven interaction with regulatory bodies as well as successes in capital raising will surely be a tremendous asset to Izun."

Mr. Talley commented, "I am very excited to join the team at Izun. The Company has an exciting portfolio of pipeline products that are poised to deliver substantial benefits to patients and therefore shareholder value. Izun's unique skills can harness the power of botanical products coupled with a potentially favorable regulatory pathway is particularly attractive. The ongoing clinical programs are expected to deliver near term milestones that will fuel growth for the Company at this transformative stage."

About Izun Pharmaceuticals

Izun Pharmaceuticals is a US based clinical stage pharmaceutical company with a wholly owned R&D center in Israel. Izun's technology platform allows it to develop botanical drugs by optimizing and purifying the extracted botanical compounds to yield polymolecular drug candidates. These patented products are designed to impact on multiple specific receptor targets. The main therapeutic focus is on agents that can reduce inflammation and accelerate healing. Izun is currently active in developing therapeutic products for a number of indications including: oral care, oncology support, wound care, women's health care, gastrointestinal disease and dermatologic conditions. Izun uses the inherent advantage of the natural botanical sources to deliver robust clinical results with an excellent safety profile. Izun has currently received approval for a number of oral care products that are marketed. Additional clinical studies are in progress for indications, including diabetic foot ulcers and atrophic vaginitis.

Izun Disclosure Notice: This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control.

Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.


View source version on businesswire.com: http://www.businesswire.com/news/home/20150722005587/en/

Health Care Industry
Endo Pharmaceuticals
Chief Executive Officer
Contact:
Izun Pharmaceuticals Corporation
Jack Talley, 212-618-6357
Chief Executive Officer
[email protected]
or
Dr. William Z. Levine, 212-618-6357
Executive Chairman
[email protected]
Fax: 212-618-6309
www.izunpharma.com

Suggested Articles

The top dose of Regeneron's COVID-19 antibody lowered virus levels and relieved symptoms more quickly than placebo in non-hospitalized patients.

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.